Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Section 3 of 6

Product information and disease description

302 evidence topics · 115 sources

Product description

Phase of product development

Product information

Generic, brand name and therapeutic class of product
Development code and substance synonyms
Brand name

No evidence found.

Dosage forms and strengths
Investigational product form and route in the pivotal trial
Registry fieldQuoted record
Pharmaceutical form“VIAL FOR INTRAVENOUS USE”
Route“SOLUTION FOR INFUSION”
Active substance origin“Protein - Other”
Vial strength and commercial formulation

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Dose-selection rationale for 1500 mg weekly
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Ficerafusp alfa
Effects of Ficerafusp alfa on other drugs
Effect on pembrolizumab pharmacokinetics or on cytochrome P450 substrates

No evidence found.

Dosing and administration
Dosage
Administration
Access and distribution
Commercial distribution arrangements and patient assistance

No evidence found.

Co-prescribed/Concomitant therapies
Effect of Ficerafusp alfa on quality measures
Product-specific effects on healthcare quality measures

No evidence found.

Product comparison
Cetuximab plus platinum and fluorouracil (EXTREME): efficacy results
OutcomeResult
Median overall survival, cetuximab with platinum-based therapy and fluorouracil (n=222), months“10.1”
Median overall survival, platinum-based therapy and fluorouracil (n=220), months“7.4”
Overall survival hazard ratio (95% CI)“0.80 (0.64, 0.98)”
Median progression-free survival, cetuximab arm, months“5.5”
Median progression-free survival, control arm, months“3.3”
Objective response rate, cetuximab arm“35.6%”
Objective response rate, control arm“19.5%”
Amivantamab plus pembrolizumab: OrigAMI-4 cohort 2, first-line, p16-positive oropharyngeal cancer excluded
Enfortumab vedotin plus pembrolizumab: EV-202 first-line cohort

“Eligible patients had R/M HNSCC, programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥1, and no prior systemic therapy in the R/M setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary analysis included 41 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sixteen patients achieved a response, and cORR was 39% [95% confidence interval (CI), 24.2–55.5]. The complete response rate was 9.8%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median PFS was 5.1 months (95% CI, 3.5–not estimable).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In patients with p16-positive oropharyngeal cancer ( n = 11), the cORR was 81.8%, in contrast to 23.3% in patients with non-HPV–associated disease ( n = 30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“b For oropharyngeal squamous cell carcinoma only, patients without oropharyngeal cancer were considered HPV–negative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients also did not undergo any testing to confirm their HPV status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of HPV-negative head and neck squamous cell carcinoma
HPV-negative share of U.S. oropharyngeal squamous cell carcinoma
Oropharynx, United States, 2012 to 2016Quoted value
Average annual reported cases“19,000”View highlighted excerpt for this quote
Attributable to 9vHPV-targeted types, number (%)“12,600 (66)”View highlighted excerpt for this quote
Attributable to other HPV types, number (%)“900 (5)”View highlighted excerpt for this quote
HPV-negative, number (%)“5,500 (29)”View highlighted excerpt for this quote
Prevalence of HPV-negative head and neck squamous cell carcinoma
Prevalence of HPV-negative or recurrent or metastatic disease

No evidence found.

Natural history, survival, and mortality
Stage at diagnosis and five-year relative survival, all oral cavity and pharynx cancer
SEER stagePercent of casesFive-year relative survival
Localized“26%”“88.7%”
Regional“55%”“69.7%”
Distant“12%”“36.0%”
Unstaged“6%”“62.3%”
Stage at diagnosis and five-year relative survival, all laryngeal cancer
SEER stagePercent of casesFive-year relative survival
Localized“49%”“79.8%”
Regional“30%”“49.4%”
Distant“15%”“36.0%”
Unstaged“6%”“57.0%”
Median overall survival with first-line pembrolizumab regimens in recurrent or metastatic HNSCC at 4-year follow-up
Pathophysiology
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of HPV-negative head and neck squamous cell carcinoma
Humanistic burden and health-related quality of life
Economic burden and healthcare resource utilization
Economic impact of HPV-negative head and neck squamous cell carcinoma on families
Economic impact of diagnostic testing

Approaches to treatment

Current treatment options and standard of care
PD-1 inhibitor monotherapy
KEYNOTE-048 design, stratification, and population

“The efficacy of KEYTRUDA was investigated in KEYNOTE-048 (NCT02358031), a randomized, multicenter, open-label, active-controlled trial conducted in 882 patients with metastatic HNSCC who had not previously received systemic therapy for metastatic disease or with recurrent disease who were considered incurable by local therapies.” (opens the source at this quote in a new tab)

“Randomization was stratified by tumor PD-L1 expression (TPS ≥50% or <50%) according to the PD-L1 IHC 22C3 pharmDx assay, HPV status according to p16 IHC (positive or negative), and ECOG PS (0 vs. 1).” (opens the source at this quote in a new tab)

“A retrospective re-classification of patients’ tumor PD-L1 status according to CPS using the PD-L1 IHC 22C3 pharmDx assay was conducted using the tumor specimens used for randomization.” (opens the source at this quote in a new tab)

“The main efficacy outcome measures were OS and PFS as assessed by BICR according to RECIST v1.1 (modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ) sequentially tested in the subgroup of patients with CPS ≥20, the subgroup of patients with CPS ≥1, and the overall population.” (opens the source at this quote in a new tab)

“Twenty-two percent of patients’ tumors were HPV-positive, 23% had PD-L1 TPS ≥50%, and 95% had Stage IV disease (Stage IVA 19%, Stage IVB 6%, and Stage IVC 70%).” (opens the source at this quote in a new tab)

“Eighty-five percent of patients’ tumors had PD-L1 expression of CPS ≥1 and 43% had CPS ≥20.” (opens the source at this quote in a new tab)

KEYNOTE-048 efficacy of pembrolizumab monotherapy at the interim analysis: CPS ≥1 and CPS ≥20 subgroups
EndpointCPS ≥1CPS ≥20
Participants, pembrolizumab 200 mg every 3 weeks“n=257”“n=133”
Participants, cetuximab with platinum and FU“n=255”“n=122”
Median OS, pembrolizumab, months (95% CI)“12.3 (10.8, 14.9)”“14.9 (11.6, 21.5)”
Median OS, cetuximab with platinum and FU, months (95% CI)“10.3 (9.0, 11.5)”“10.7 (8.8, 12.8)”
OS hazard ratio (95% CI)“0.78 (0.64, 0.96)”“0.61 (0.45, 0.83)”
Median PFS, pembrolizumab, months (95% CI)“3.2 (2.2, 3.4)”“3.4 (3.2, 3.8)”
Median PFS, cetuximab with platinum and FU, months (95% CI)“5.0 (4.8, 5.8)”“5.0 (4.8, 6.2)”
PFS hazard ratio (95% CI)“1.15 (0.95, 1.38)”“0.97 (0.74, 1.27)”
ORR, pembrolizumab (95% CI)“19% (14.5, 24.4)”“23% (16.4, 31.4)”
ORR, cetuximab with platinum and FU (95% CI)“35% (29.1, 41.1)”“36% (27.6, 45.3)”
Median duration of response, pembrolizumab, months (range)“20.9 (1.5+, 34.8+)”“20.9 (2.7, 34.8+)”
Median duration of response, cetuximab with platinum and FU, months (range)“4.5 (1.2+, 28.6+)”“4.2 (1.2+, 22.3+)”
KEYNOTE-048 primary publication: pembrolizumab monotherapy overall survival

“Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

KEYNOTE-048 four-year follow-up: pembrolizumab monotherapy

“The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994; Figs 2A-2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pembrolizumab alone did not improve ORR compared with cetuximab-chemotherapy in the PD-L1 CPS ≥ 20, CPS ≥ 1, or total populations (Data Supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A survival plateau at approximately 20% became apparent around the 4-year landmark for all patients receiving pembrolizumab alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

PD-1 inhibitor plus platinum and fluorouracil
KEYNOTE-048 efficacy of pembrolizumab with platinum and fluorouracil at the interim analysis: overall population
EndpointPembrolizumab with platinum and FUCetuximab with platinum and FU
Participants“n=281”“n=278”
Median OS, months (95% CI)“13.0 (10.9, 14.7)”“10.7 (9.3, 11.7)”
OS hazard ratio (95% CI)“0.77 (0.63, 0.93)”Reference
Median PFS, months (95% CI)“4.9 (4.7, 6.0)”“5.1 (4.9, 6.0)”
PFS hazard ratio (95% CI)“0.92 (0.77, 1.10)”Reference
ORR (95% CI)“36% (30.0, 41.5)”“36% (30.7, 42.3)”
Median duration of response, months (range)“6.7 (1.6+, 30.4+)”“4.3 (1.2+, 27.9+)”
KEYNOTE-048 four-year follow-up: pembrolizumab with chemotherapy

“The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population (HR, 0.71; 95% CI, 0.59 to 0.85; nominal one-sided P = .00008; Figs 2D-2F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Any-grade treatment-related AEs occurred in 58.3% (n = 175) of patients in the pembrolizumab-alone group, 95.7% (n = 264) in the pembrolizumab-chemotherapy group, and 96.9% (n = 278) in the cetuximab-chemotherapy group (Data Supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Grade ≥ 3 treatment-related AEs were reported in 17.0% (n = 51), 71.7% (n = 198), and 69.3% (n = 199) of patients, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

EGFR monoclonal antibody plus platinum-based chemotherapy
EXTREME efficacy in the label
EndpointCetuximab with platinum-based therapy and fluorouracilPlatinum-based therapy and fluorouracil
Participants“(n=222)”“(n=220)”
Median OS, months“10.1”“7.4”
OS hazard ratio (95% CI)“0.80 (0.64, 0.98)”Reference
Median PFS, months“5.5”“3.3”
PFS hazard ratio (95% CI)“0.57 (0.46, 0.72)”Reference
ORR“35.6%”“19.5%”
Cytotoxic chemotherapy
Therapies after progression on PD-1 inhibitor and platinum
OrigAMI-4: efficacy results
OutcomeRYBREVANT FASPRO (N=102)
Overall response rate (95% CI)“42% (32%, 52%)”
Complete response“15%”
Partial response“28%”
Duration of response, range (months)“1.4+, 19.7+”
Patients with duration of response of 6 months or longer“56%”
Salvage surgery and reirradiation for locoregional recurrence
Limitations of current therapies
Summary: response, survival, and PD-L1 selection with first-line pembrolizumab regimens

Pembrolizumab monotherapy is approved for first-line recurrent or metastatic HNSCC with PD-L1 CPS ≥1, and pembrolizumab with platinum and fluorouracil for all first-line patients. ASCO states that “Response rates to single-agent pembrolizumab remain close to 20%, regardless of prior exposure to therapy or PD-L1 expression”. At the KEYNOTE-048 4-year follow-up, the objective response rate with pembrolizumab alone was 19.1% versus 34.9% with cetuximab-chemotherapy in the CPS ≥1 population and 16.9% versus 36.0% in the total population; with pembrolizumab-chemotherapy it was 37.2% (CPS ≥1) and 36.3% (total). Neither pembrolizumab regimen improved progression-free survival at the second interim analysis, when median progression-free survival in the CPS ≥1 subgroup was 3.2 months with pembrolizumab versus 5.0 months with cetuximab-chemotherapy. At the 4-year follow-up, median overall survival was 12.3 months with pembrolizumab (CPS ≥1) and 13.0 months with pembrolizumab-chemotherapy (total population); 5-year overall survival in the total population was 14.4% and 16.0%, and the survival curve with pembrolizumab alone reached a plateau at approximately 20%. The median duration of pembrolizumab exposure was 3.5 months with monotherapy and 5.8 months in the combination arm. In exploratory analyses that were not prespecified, median overall survival with pembrolizumab alone versus cetuximab-chemotherapy was 10.8 versus 10.1 months in the CPS 1-19 subgroup (hazard ratio 0.86, 95% CI 0.66 to 1.12), and median overall survival was 7.9 versus 11.3 months in the CPS <1 subgroup (hazard ratio 1.51, 95% CI 0.96 to 2.37).

Summary: toxicity and administration of chemotherapy-containing regimens

At the KEYNOTE-048 4-year follow-up, grade ≥3 treatment-related adverse events occurred in 17.0% of participants receiving pembrolizumab alone, 71.7% receiving pembrolizumab-chemotherapy, and 69.3% receiving cetuximab-chemotherapy. Fluorouracil requires a “continuous 4-day infusion” and is associated with “cardiovascular and gastrointestinal toxicities”. In EXTREME, fatal cardiac disorders or sudden death occurred in 3% of 219 participants treated with cetuximab plus platinum and fluorouracil. With a taxane in place of fluorouracil alongside pembrolizumab and carboplatin, grade 3 to 5 treatment-related adverse events occurred in 76 of 101 treated participants (75%). NCI states that chemotherapy has been shown to induce responses with no demonstrated increase in survival; in randomized trials, cisplatin plus fluorouracil did not improve overall survival over methotrexate, and response rates were 32% with cisplatin plus fluorouracil and 10% with methotrexate in one trial, and 27% with cisplatin plus fluorouracil and 26% with cisplatin plus paclitaxel in another.

Summary: outcomes in HPV-negative disease

Response and survival with current therapy are lower in HPV-negative than in HPV-positive disease. In Argiris et al. (2014), the objective response rate was 19% for HPV-negative versus 55% for HPV-positive tumors, and median survival was 6.7 versus 12.9 months. After progression of oropharyngeal cancer, 2-year overall survival was 27.6% for p16-negative versus 54.6% for p16-positive disease. With first-line pembrolizumab in U.S. practice, median real-world overall survival in HPV-negative versus HPV-positive disease was 9 versus 20 months on monotherapy and 7 versus 15 months with chemotherapy. ASCO states that current data “do not support changing recommendations” for anti-PD-1 therapy “with regard to the HPV status.”

Summary: options after progression and for locoregional recurrence

The FDA states that approved therapies after platinum-based chemotherapy are associated with an overall response rate of around 20% or less. On November 5, 2026, amivantamab and hyaluronidase-lpuj received accelerated approval after progression on platinum-based chemotherapy and an anti-PD-(L)1 antibody, excluding HPV-associated oropharyngeal squamous cell carcinoma, based on an overall response rate of 42% in the 102-participant primary efficacy population of OrigAMI-4, a multicenter, open-label, multi-cohort trial. Conventional salvage regimens yield response rates of 21% to 69%, median progression-free survival of 2.9 to 5.5 months, and median overall survival of 6.3 to 13.3 months, and a review states that there is “no clear standard of care choice in second-line treatment”. For locoregional recurrence after prior radiation, reirradiation with intensity-modulated radiotherapy had pooled late grade ≥3 and grade 5 toxicity rates of 26% and 3.1%, and postoperative reirradiation with chemotherapy after salvage surgery improved disease-free survival without a significant effect on overall survival.

Place in treatment, anticipated use, and care setting
Summary: target population

The Breakthrough Therapy Designation covers ficerafusp alfa with pembrolizumab “for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.” The pivotal FORTIFI-HN01 trial (NCT06788990) enrolls recurrent or metastatic HNSCC with a primary tumor in the “oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC)”; paranasal sinus and nasopharyngeal primaries are excluded. The EU trial record requires “documentation of HPV-negative disease per central testing performed if presenting with OPSCC”, and lists the development of an HPV DNA assay among the sponsor's delegated duties. HPV status is therefore established by testing only for oropharyngeal primaries; Bicara states that HPV testing is “typically only being conducted in tumors originating from the oropharynx”, and the College of American Pathologists recommends against routine HR-HPV testing of primary oral cavity, laryngeal, nasopharyngeal, and hypopharyngeal carcinomas for prognostic purposes. Participants must have “PD-L1 CPS ≥1”, which the EU record specifies as “PD-L1 immunohistochemistry [IHC] via 22C3” in participants eligible “to receive pembrolizumab as frontline monotherapy”. Other criteria are no prior systemic therapy in the recurrent or metastatic setting, systemic therapy for locoregionally advanced disease completed more than 6 months earlier, no prior anti-EGFR antibody outside radiosensitizing or multimodal treatment, no immune checkpoint inhibitor within 6 months, measurable disease by RECIST 1.1, ECOG performance status 0 or 1, and no higher risk of bleeding.

Summary: position relative to current first-line therapy

Ficerafusp alfa would be added to pembrolizumab in first-line treatment, the setting in which pembrolizumab monotherapy (CPS ≥1) and pembrolizumab with platinum and fluorouracil are FDA approved, offered by ASCO with a strong recommendation for CPS ≥1, and listed by NCCN as preferred first-line options. The intended population overlaps the pembrolizumab monotherapy label population, which requires CPS ≥1 by an FDA-authorized test. Hanna et al. state that the combination “could provide a chemotherapy-free regimen”. Bicara reports a “two-to-three-fold increase in median OS” relative to pembrolizumab monotherapy or pembrolizumab with chemotherapy, and states that “No head-to-head studies have been conducted, and cross-trial comparisons may not be reliable”. The available results for ficerafusp alfa are from a single-arm phase 1b trial; topline results of the FORTIFI-HN01 interim analysis are expected in mid-2027, with a potential U.S. launch in 2028.

Summary: anticipated use and care setting

Bicara estimates about 50,000 HPV-negative patients newly diagnosed each year in the United States, EU5, and Japan, about 18,000 of them in the United States, and states that 80% of recurrent or metastatic HNSCC is HPV-negative. In KEYNOTE-048, 85% of tumors had CPS ≥1; among U.S. real-world first-line pembrolizumab recipients with a CPS result (352 participants, 54.5% of the cohort), 83.8% had CPS ≥1. In a U.S. nationwide database drawn primarily from community practices, 32.7% of 2,207 participants with recurrent or metastatic HNSCC received PD-L1 testing before first-line therapy and 50.0% were never tested. In the phase 1b trial, ficerafusp alfa 1,500 mg was given intravenously on days 1, 8, and 15 of 21-day cycles with pembrolizumab 200 mg on day 1; the protocol specifies a 120-minute infusion, extendable to 4 hours, and observation with vital-sign monitoring for 2 hours after the first 2 doses. Bicara is developing a less frequent dosing regimen. Among U.S. real-world first-line pembrolizumab recipients, 583 (90.2%) were treated in community practices and 57 (8.8%) in academic practices.

Company estimate of the target population
PopulationCompany estimate
HPV-negative patients newly diagnosed each year in the United States, EU5, and Japan“~50K”
Of those, patients in the United States“~18K”
Heterogeneity of treatment effect
Confirmed response by CPS, tumor burden, and disease extent across the three dose cohorts
Subgroup, % (n/N)750 mg weekly (n=30)1500 mg weekly (n=28)2000 mg every 2 weeks (n=27)
CPS 1-19“73 (8/11)”“54 (7/13)”“57 (8/14)”
CPS 20 or greater“47 (9/19)”“53 (8/15)”“38 (5/13)”
Sum of target lesion diameters 50 mm or less“55 (11/20)”“53 (8/15)”“53 (9/17)”
Sum of target lesion diameters greater than 50 mm“60 (6/10)”“54 (7/13)”“40 (4/10)”
Sum of target lesion diameters greater than 70 mm“50 (2/4)”“43 (3/7)”“33 (2/6)”
Locoregional disease only“38 (6/16)”“62 (5/8)”“50 (7/14)”
Distant metastatic disease only“100 (5/5)”“29 (2/7)”“40 (2/5)”
Locoregional and distant metastatic disease“67 (6/9)”“62 (8/13)”“50 (4/8)”
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy